Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition

ELZONRIS was approved by the FDA in December 2018 for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older, in both treatment-naïve ...
AlphaGalileo

Crigler-Najjar syndrome type 2 complicating cholecystitis in a patient with UGT1A1 gene double homozygous mutations

Crigler-Najjar syndrome (CNS) and Gilbert syndrome (GS) are rare autosomal recessive disorders causing unconjugated hyperbilirubinemia due to reduced ...
Blavity on MSN

Exploring The Health Benefits Of Butterfly Pea Flower Tea

Some early human studies link butterfly flower pea to improved heart health, cognition, liver health and stress reduction, ...
Cantech Letter

Fidelity Investments Canada ULC Announces Estimated 2025 Annual Reinvested Capital Gains Distributions for Fidelity ETFs and ETF Series of Fidelity Mutual Funds

Fidelity Investments Canada ULC (“Fidelity”) today announced the estimated 2025 annual reinvested capital gains distributions for Fidelity’s suite of ETFs ...
Le Lézard

Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium

Eli Lilly and Company today announced that new data from across its breast oncology portfolio and pipeline will be featured at the San Antonio Breast Cancer Symposium (SABCS), taking place December 9?